This is intended for HCPs practising in Great Britain (England, Scotland, Wales) only.
Prescribing Information for SARCLISA®▼ (isatuximab) can be found via the Product Card at the bottom of the page.
Stay up-to-date on Multiple Myeloma and our products related to the disease.
SARCLISA ®▼(isatuximab) in Clinical Practice: A Real World Case Study – Dr Karthik Ramasamy
Relapsed Refractory Multiple Myeloma
Date of Preparation: September 2023
▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.